TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a confirmed diagnosis of partial-onset seizures with or without secondary generalization for at least 12 months prior to Visit 1.~* Currently on a stable dosing regimen of 1 to 3 AEDs for at least 4-weeks prior to Visit 1 (12 weeks for phenobarbital and primidone).~* Have a minimum of 8 partial-onset seizures and no more than 21 consecutive seizure free days, during the 8-week baseline.~Exclusion Criteria:~* Have a history of seizure episodes lasting less than 30 minutes in which several seizures occur with such frequency that the initiation and completion of each individual seizure cannot be distinguished, within 3 months prior to Visit 1.~* Have a history of pseudoseizures, or status epilepticus, within 3 months prior to Visit 1.~* Have a history of metabolic acidosis, nephrolithiasis, ureterolithiasis, or narrow angle glaucoma.~* Have a history of suicidal attempts, suicidal ideation, or uncontrolled psychiatric illness within 2 years of Visit 1.~* Currently taking, or have taken felbamate within the past 18 months, or have taken vigabatrin in the past.~* Have taken topiramate within the past 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- USL255 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 40 years of age, in our outpatient clinic with chronic cough and COPD (gold2-4)~* Chronic cough is defined as a cough \> 12 weeks duration, at least 12 weeks a year in 2 subsequent years.~* Analysed for bronchiectasis prior to participation by CT-thorax.~Exclusion Criteria:~* Prior history of asthma~* Use of i.v. or oral corticosteroids and or antibiotics for an exacerbation 3 weeks before inclusion~* Patients suffering from other relevant lung diseases.~* Clinically relevant abnormal laboratory values suggesting an unknown disease requiring further clinical evaluation.~* Liver disease, (ALAT and/or ASAT levels two or more times the upper limit of normal).~* Pregnancy or lactation.~* Use of macrolides the last 6 weeks prior to inclusion.~* Allergy or intolerance to macrolides.~* Other research medication started 2 months prior to inclusion.~* Prior randomisation in this study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient \> 45 years of age~* Out-patient diagnosed with primary osteoarthritis of the femorotibial medial joint of the knee with clinical and radiological (Kellgren grade II-III) ACR diagnosis~* Joint Space Width (JSW) \> 2mm~* Overall pain greater or equal to 55mm (VAS - Visual Analogue Scale 100mm) recorded in the knee,by the patient at any time during the week prior to the evaluation~Exclusion Criteria:~* Overweight patients (body mass index \> 32).~* Pregnant and lactating women. Women of child-bearinge age not using effective contraception~* Patients who have received intra-articular hyaluronic acid within the previous year and/or intra-articular steroids or articular lavage in the chosen knee,within the previous 3 months prior to their inclusion in the study.~* AINE administration within the 14 days prior to their inclusion in the study.~* Administration of glucosamine sulphate, chondroitin sulphate and diacerein within the 3 months prior to their inclusion in the study.~* Immunocompromised patients or patients receiving systemic immunosuppressive therapy.~* Patients with known sensitivity to HA, parcetamol or AINEs permitted as rescue medication.~* Patients who have received any investigational drug within 30 days prior to visit 1, or who are scheduled for the administration of an investigational drug other than the protocol product during this study.~* Patients with severely impaired central nervous system.~* Patients with coagulation alterations, despite receiving treatment.~* Patients with secondary osteoarthritis of the knee~* Patients having previously received surgery, including arthroscopy~* Patients with articular inflammatory disease

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hyaluronic acid (Type: EXPERIMENTAL): Cycles of 5 injections of hyaluronic acid at specified intervals
- Placebo (Type: PLACEBO_COMPARATOR): Cycles of 5 injections of saline at specified intervals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fenoldopam in Pediatric Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with congenital heart disease, less than one year old, undergoing surgery with the use of cardiopulmonary bypass~Exclusion Criteria:~* Children over one year old, correction for ventricular or atrial septal defect, need for deep hypothermic circulatory arrest, preoperative renal dysfunction.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 365 Days
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Saline blinded infusion
- Fenoldopam (Type: ACTIVE_COMPARATOR): Drug infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female or male individuals ≥ 18 years~* Patients with acute Rhinosinusitis which are treated with Ectoin® Rhinitis Nasal Spray or Sinupret forte during the observational period~Exclusion Criteria:~* Contra indications according to the label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of a lead-in study (NCT00891462)~Exclusion Criteria:~* Use or anticipated use of any medication prohibited in this study~* Evidence of abnormal clinical laboratory values, vital signs, or electrocardiographic (ECG) results or the presence of abnormities in physical examination findings~* The presence of anti-cholinergic effects (eg, dry mouth, urinary retention, narrow angle glaucoma)~* QTcB of \>500 msec on both the pre-dose and post-dose ECG~* Women who are pregnant, intend to become pregnant, or are breast-feeding~* A life expectancy of less than 1 year~* Noncompliance with IP dosing and/or attending clinic visits during the lead-in study~* Significant interruption of double-blind therapy during the transition from the lead-in study into the extension study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 52 weeks of treatment
- 2 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 52 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Postmenopausal women with osteoporosis, defined as low bone mineral density (BMD T-score at the total hip or femoral neck of ≤ -2.50)~Exclusion Criteria:~* BMD T-score of ≤ -3.50 at the total hip or femoral neck~* History of hip fracture~* Any severe or more than 2 moderate vertebral fractures, as assessed by the central imaging based on lateral spine x-rays~* Use of agents affecting bone metabolism~* History of metabolic or bone disease (except osteoporosis)~* Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)~* Current hyper- or hypocalcemia~* Current, uncontrolled hyper- or hypothyroidism~* Current, uncontrolled hyper- or hypoparathyroidism

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmation of metastatic or recurrent renal cell carcinoma~Exclusion Criteria:~* Certain types of previous anti-cancer therapy for Renal Cell Carcinoma~* Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes~* Patients with a history of poorly controlled high blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Cediranib placebo
- 2 (Type: EXPERIMENTAL): Cediranib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 diabetes~* Diabetic retinopathy~* Age 18-70~* Both sexes~Exclusion Criteria:~* Age \<18 or \>70 at enrollment~* Hereditary muscle disorders~* Uncontrolled hypothyroidism~* Elevated alcohol consumption~* Renal failure~* Hepatic failure~* Allergy to fenofibrate or excipients~* Acute / chronic pancreatitis~* Pregnancy and lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fenofibrate (Type: EXPERIMENTAL): Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral tablets daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients satisfying the Rome III Diagnostic Criteria~2. Patients whose ≥25% of stools were loose or watery and \<25% of them were hard or lumpy stools~3. Patients who have abdominal pain or discomfort~4. Patients in whom after occurrence of IBS symptoms the following tests were conducted and in whom no organic changes were observed Pancolonoscopy or contrast enema~Exclusion Criteria:~1. Patients with a history of surgical resection of the stomach, gallbladder, small intestine or large intestine~2. Patients with a history or current evidence of inflammatory bowel disease~3. Patients with a history or current evidence of colitis ischemic~4. Patients with concurrent infectious enteritis~5. Patients with concurrent hyperthyroidism or hypothyroidism~6. Patients with concurrent active peptic ulcer~7. Patients with other concurrent disease that may affect the digestive tract passage or large intestinal function or that is likely to interfere with proper assessment of IBS abdominal pain/discomfort

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- YM060 group (Type: EXPERIMENTAL): None
- Placebo group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known coronary artery disease~* On maintenance treatment with aspirin (81 mg per day) and clopidogrel (75 mg per day) for at least 1-month as per standard of care.~* Age between 18 and 74 years old.~Exclusion Criteria:~* History of stroke, transient ischemic attack or intracranial bleeding.~* Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel.~* Weight \<60kg~* On treatment with oral anticoagulation (coumarin derivate, dabigatran).~* Hemoglobin\<10 gm/dL~* Platelet count \<80x106/mL~* Active bleeding or hemodynamic instability.~* Creatinine Clearance \<30 mL/minute.~* Baseline ALT \>2.5 times the upper limit of normal.~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~* Drugs interfering with 2C19 metabolism (to avoid interaction with clopidogrel): , fluconazole (Diflucan), ketoconazole (Nizoral), voriconazole (VFEND), etravirine (Intelence), felbamate (Felbatol), fluoxetine (Prozac, Serafem, Symbyax), fluvoxamine (Luvox), and ticlopidine (Ticlid).~* Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant females\*. \*Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: ACTIVE_COMPARATOR): Prasugrel 60mg loading dose and 10 mg maintenance dose
- Ticagrelor (Type: ACTIVE_COMPARATOR): Ticagrelor 180mg loading dose and 90mg bid maintenance dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anakinra and Kawasaki Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, male and female, at any age ≥ 3 months (5 kg) of life, with KD according to the American Heart Association definition for complete or incomplete KD. fever ≥ 5 days and ≥ 4 of 5 main clinical signs: modification of the extremities, polymorphic exanthema, bilateral bulbar not exudative conjunctivitis, erythema of the lips or oral cavity, and cervical lymph nodes usually unilateral \> 1.5 cm in diameter. In the presence of less than 4 clinical criteria and 5 days of fever, the diagnosis of disease KD is proposed in case of coronary abnormalities (at least one dilated coronary artery with internal diameter ≥ 2,5 SD from the mean normalized for body surface area (Z score) as determined by echocardiography. For indicative purpose, in case of incomplete KD, other biological supportive criteria for incomplete KD can help to ensure the diagnosis: leucocytosis, elevated CRP, elevated ESR, anaemia, hyponatremia, elevated ASAT, ALAT and gGT, hyperlipidaemia.~* Patients who failed to respond to standard therapy of KD:, e.g. Persistence or recrudescence of fever ≥ 38°C, 48 hours after the infusion of 2g/kg of IV Ig,~* Weight ≥5Kg~* Patient, parent or legal guardian's written informed consent is required~* Patient with health insurance~* Patient agrees to have effective contraception for the duration of participation in the research~Exclusion Criteria:~* Preterm and neonates, pregnancy~* Patients suspected with another diagnosis~* Patients with overt concomitant bacterial infection~* Patients previously treated with another biotherapy~* Patients with any type of immunodeficiency or cancer~* Patients with increased risk of TB infection~* Recent tuberculosis infection or with active TB~  * Close contact with a patient with TB~ * Patients recently arrived less than 3 months from a country with high prevalence of TB~ * A chest radiograph suggestive of TB~* Patients with end stage renal disease: NKF stages ≥4; eGFR≤29mL/min/1.73 m2 or diabetes mellitus or neutropenia \<1500/mm3 or liver failure~* Hypersensitivity to the active substance or to any of the excipients (citric acid and anhydrous; sodium chloride disodium edetate dehydrate polysorbate 80; sodium hydroxide; water for injections)~* Patient already included in a biomedical research other than observational (e.g.; cohort, registry)

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis~* Patients with a relapsing-remitting disease course~* Patients with expanded disability status scale (EDSS) score of 0-5.5~Exclusion Criteria:~* Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc.~* Pregnant or nursing women~For inclusion in the extension phase patients should complete the 24 month core study with or without 24 months on study drug. If a patient discontinued study drug during the core study due to an adverse event, serious adverse event, laboratory abnormality etc. they would be excluded from the Extension Phase.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 1.25 mg (Type: EXPERIMENTAL): Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day.
- Fingolimod 0.5 mg (Type: EXPERIMENTAL): Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
- Placebo (Type: EXPERIMENTAL): Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete